Xeris Biopharma Holdings
XERS
49 hedge funds and large institutions have $161M invested in Xeris Biopharma Holdings in 2019 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 2 reducing their positions, and 4 closing their positions.
1,050% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 2
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
40% more funds holding
Funds holding: 35 → 49 (+14)
7.7% more ownership
Funds ownership: 51.72% → 59.43% (+7.7%)
12% less capital invested
Capital invested by funds: $184M → $161M (-$22.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.4M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$9.57M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.74M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$7.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$3.45M |
| 2 |
DM
Deerfield Management
New York
|
-$1.84M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.4M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$17K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GIM
51
Granahan Investment Management
Waltham,
Massachusetts
| – | -$1.4M | -82,504 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$17K | -1,016 | Closed |
|
|
53
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$2K | -94 | Closed |
|
XERS Hedge Fund Activity: Q1 2019 in Review
49 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2019, worth a combined $161M — down 12% from $184M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new XERS positions and 4 closed out — a net gain of 14 holders — while 23 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, adding an estimated $14.7M. The largest seller was Sabby Management, exiting entirely with an estimated $3.45M sold.
- 49 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2019, up from 35 in Q4 2018.
- Funds reported $161M of Xeris Biopharma Holdings stock for Q1 2019, down 12% quarter-over-quarter.
- 18 funds opened new Xeris Biopharma Holdings positions in Q1 2019 and 4 closed out, a net change of +14 holders.
- The largest Xeris Biopharma Holdings buyer in Q1 2019 was BlackRock, an estimated $14.7M added.
- The largest Xeris Biopharma Holdings seller in Q1 2019 was Sabby Management, an estimated $3.45M sold.
Based on aggregated 13F filings for Q1 2019.